Growth Metrics

Lineage Cell Therapeutics (LCTX) Income from Non-Controlling Interests (2016 - 2025)

Historic Income from Non-Controlling Interests for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $29000.0.

  • Lineage Cell Therapeutics' Income from Non-Controlling Interests fell 1212.12% to $29000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $148000.0, marking a year-over-year increase of 12769.23%. This contributed to the annual value of $27000.0 for FY2024, which is 28571.43% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Income from Non-Controlling Interests stood at $29000.0 for Q3 2025, which was down 1212.12% from $100000.0 recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Income from Non-Controlling Interests ranged from a high of $100000.0 in Q2 2025 and a low of -$200000.0 during Q4 2021
  • Over the past 5 years, Lineage Cell Therapeutics' median Income from Non-Controlling Interests value was -$8000.0 (recorded in 2021), while the average stood at -$9052.6.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Income from Non-Controlling Interests plummeted by 163846.15% in 2021, and later skyrocketed by 86923.08% in 2025.
  • Lineage Cell Therapeutics' Income from Non-Controlling Interests (Quarter) stood at -$200000.0 in 2021, then surged by 96.0% to -$8000.0 in 2022, then soared by 862.5% to $61000.0 in 2023, then crashed by 62.3% to $23000.0 in 2024, then grew by 26.09% to $29000.0 in 2025.
  • Its Income from Non-Controlling Interests was $29000.0 in Q3 2025, compared to $100000.0 in Q2 2025 and -$4000.0 in Q1 2025.